Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00938626 · ClinicalTrials.gov registry record · Phase 1
Treated T Cells Followed by a Stem Cell Transplant in Treating Patients With Multiple Myeloma
A Phase 1 study, sponsored by Barbara Ann Karmanos Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00938626 is a Phase 1 study that has completed, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 12 participants.
The verdict
NCT00938626, a Phase 1 study, has completed, sponsored by Barbara Ann Karmanos Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
RATIONALE: Giving chemotherapy followed by treated T cells before a stem cell transplant stops the growth of cancer cells by stopping them from dividing or by killing them. After treatment, stem cells are collected from the patient's blood and stored. High-dose chemotherapy is given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. PURPOSE: This phase I trial is studying the side effects and best way to give treated T cells followed by stem cell transplant in treating patients with multiple myeloma.
Interventions
- PROCEDURE autologous hematopoietic stem cell transplantation
- PROCEDURE peripheral blood stem cell transplantation
- BIOLOGICAL anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2009-10 |
| Est. Completion | 2013-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00938626
The ClinicalTrials.gov registry entry for NCT00938626 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Barbara Ann Karmanos Cancer Institute, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which autologous hematopoietic stem cell transplantation is the first listed.
NCT00938626 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00938626 about?
NCT00938626 is a clinical study titled "Treated T Cells Followed by a Stem Cell Transplant in Treating Patients With Multiple Myeloma". RATIONALE: Giving chemotherapy followed by treated T cells before a stem cell transplant stops the growth of cancer cells by stopping them from dividing or by killing them. After treatment, stem cells are collected from the patient's blood and stored. High-dose chemotherapy is given to prepare the b...
What is the current status of trial NCT00938626?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2009-10. Estimated completion is 2013-03.
What interventions are being tested in trial NCT00938626?
The interventions under investigation include: autologous hematopoietic stem cell transplantation (PROCEDURE), peripheral blood stem cell transplantation (PROCEDURE), anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT00938626?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.